Journals By Industry - Biologics Mfg

CAMBRIDGE, Mass. -- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the European Medicines Agency (EMA) has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme([R])...

BERLIN -- JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of BioNTech AG (Mainz, Germany), IUCT and LEITAT (Barcelona, Spain) announced today their collaboration on the joint development of an enhanced anticancer therapy...

WILMINGTON, N.C. -- AAIPharma Services Corp. ("AAIPharma"), a leading provider of pharmaceutical product development services, announced today that it has appointed Eduardo Uribe to senior director of quality services at the company's Charleston,...

EXTON, Pa. -- Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has licensed its HibTITER[R] vaccine to Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, Japan; "MTPC") for commercialization...

TAMPA, Fla. & MINNEAPOLIs -- Biovest International, Inc. (OTCQB: "BVTI"), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: "ABPI"), today announced that Biovest has entered into a key Research Agreement with the Max...

DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/6315b9/specialty_physicia) has announced the addition of Frost & Sullivan's new report "Specialty Physicians Discuss their Opinions of the United States Biosimilars Market" to their offering. Specialty Physicians Look Forward...

Informational Portal Educates Patients, Public About Allograft Tissue ALACHUA, Fla. -- RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, has launched an informational website to educate...

GAITHERSBURG, Md. -- MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, is hosting a series of events at CHI's PepTalk 2012 being held January 9-13 in San Diego. The highlighted...

ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary 2011 financial results and provided guidance for 2012. For 2011, the Company anticipates total revenues of $270 to $275 million. With respect...

Investigational BAX 855 is based on ADVATE Factor VIII Molecule DEERFIELD, Ill. -- Baxter International Inc. (NYSE: BAX) today announced the dosing of the first patients in a Phase I clinical trial of...

CAMBRIDGE, Mass. -- Tetragenetics Inc., a biotechnology company focused on the development of recombinant vaccines, today reported preclinical study results showing that an investigational nanoparticle-based influenza vaccine protects against a highly pathogenic H5N1...

SOUTH SAN FRANCISCO, Calif. -- Tobira Therapeutics, Inc. announces the appointment of Eric Lefebvre, M.D., as Chief Medical Officer, and Martine Kraus, Ph.D., as Vice President, Regulatory Affairs. Both appointments are effective immediately....

CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 30th Annual J.P. Morgan Healthcare Conference 2012 on Wednesday,...

HEADNOTE HEALTHCARE: Laguna Niguel firm, new CEO set for Cambridge A well-funded startup biopharmaceutical is moving out of Orange County as it works on getting its products on the market. Inspiration Biopharmaceuticals Inc.,...

Multinational Manufacturers Strengths...

Strengths Strong OTC product portfolio. One of the leading global pharmaceutical companies. Long-established local manufacturing presence. Production of the influenza drug Relenza (zanamivir) which is also used as a preventative measure against avian...

Strengths...

Company Monitor Leading Local Manufacturers Strengths UCB Pharma is Belgium's largest pharmaceuticals company. Only domestic player with a strong international presence. Considerable in-house R&D programme. Weaknesses As UCB turns its efforts to biopharmaceuticals,...

Leading Foreign Companies Strengths A focus on R&D to drive growth. Significant presence in emerging markets. Weaknesses Suspension of Avandia (rosiglitazone) damaged patient and investor perception, as well as hindering the company's revenue...